Oslo, 18 June 2025: Reference is made to the stock exchange notice published by
BlueNord ASA ("BlueNord" or the "Company") on 10 June 2025 where the Company
announced its intention to declare a USD 253 million distribution in connection
with the Tyra Completion Test being met, as further described therein.

Pursuant to the authorization to the board of directors to pay dividends granted
by the annual general meeting of the Company on 22 May 2025, the board of
directors has today resolved to declare a cash dividend payment of USD 203
million, NOK 76.05 per share, to shareholders registered in the Company's
shareholder register on 25 June 2025 (record date). Consequently, BlueNord's
shares will be traded ex-dividend as of 24 June 2025. Payment date is 4 July
2025. For Norwegian tax purposes, the dividend is considered repayment of paid
-in capital. In addition, the Company intends to buy back shares of up to USD 50
million, expected to take place following BlueNord's Q2 results on 10 July 2025.
To the extent the Company elects to buy back less than USD 50 million, the
remaining amount will be paid to shareholders as a dividend. Further details and
structure related to a buyback will be announced in due course.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act and in accordance with the
requirements of the Continuing Obligations.

***

Contact:
Cathrine Torgersen, Chief Corporate Affairs Officer
Phone: +47 915 28 501
Email: cathrine.torgersen@bluenord.com

About BlueNord ASA
BlueNord is a strategically important European oil and gas company that
specialises in producing and developing energy resources, and in activities
which support the energy transition. The Company has a 36.8 percent interest in
the Danish Underground Consortium (DUC) that is responsible for oil and gas
production in the Danish North Sea. BlueNord is listed on the Oslo Stock
Exchange and trades under the ticker "BNOR". For further information, please
visit: www.bluenord.com.